Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
ICMT Inhibitor
CAY10677 is a potent inhibitor of Isoprenylcysteine carboxyl methyltransferase (ICMT), a critical enzyme involved in post-translational modifications of proteins. This compound has demonstrated significant ability to inhibit cancer cell proliferation, making it a valuable tool for cancer research. Additionally, CAY10677 exhibits favorable PAMPA permeability, enhancing its applicability in cellular assays. -
ICMT Inhibitor
UCM-13207 is a selective inhibitor of Isoprenylcysteine Carboxyl Methyltransferase (ICMT) with potential applications in aging research. This compound has been shown to mitigate progeria-like characteristics and enhance the survival rate in LmnaG609G/G609G mice, serving as an effective tool in studying cellular aging processes and related disorders. Researchers can utilize UCM-13207 to explore therapeutic strategies for age-related diseases. -
ICMT Inhibitor
J1-1 is an inhibitor of Isoprenylcysteine Carboxyl Methyltransferase (ICMT), with an IC50 of 1.0 μM. This compound demonstrates notable anticancer activity, making it a valuable tool for research into cancer biology. J1-1 can be utilized in studies focusing on protein modification and its implications in oncogenic signaling pathways. -
LTB4 inhibitor
U-75302 is a potent inhibitor of leukotriene B4, developed as a pyridine analogue. This compound demonstrates significant anti-inflammatory activity, making it valuable for research into various inflammatory diseases. U-75302 can help elucidate the role of leukotriene B4 in pathophysiological processes, contributing to better understanding and potential therapeutic strategies in inflammation-related conditions. -
PGF2α/LTB4 Inhibitor
Darbufelone is a dual inhibitor of prostaglandin F2α (PGF2α) and leukotriene B4 (LTB4) production, primarily targeting the cyclooxygenase enzyme PGHS-2 with an IC50 of 0.19 μM, while showing markedly lower potency against PGHS-1 (IC50 of 20 μM). This compound is valuable for research focused on inflammation, pain modulation, and the role of eicosanoids in various pathological conditions. Its selective inhibition of PGF2α and LTB4 makes Darbufelone a useful tool for studying the intersection of these signaling pathways in cellular responses. -
FPR Inhibitor
Boc-Phe-Leu-Phe-Leu-Phe (Boc-FLFLF) acts as an inhibitor of N-formyl peptide receptors (FPR). This compound effectively reduces FMLP-induced release of peptide leukotrienes and disrupts the sprouting of human umbilical vein endothelial cell (HUVEC) spheroids in a three-dimensional fibrin gel model, which simulates the conditions associated with proliferative diabetic retinopathy (PDR) and vascular endothelial growth factor (VEGF). Additionally, Boc-Phe-Leu-Phe-Leu-Phe counteracts the anti-inflammatory and antifibrotic effects of Ac2-26. It is suitable for applications in immunological research. -
LTB4 Inhibitor
Halometasone is a corticosteroid that functions as an inhibitor of leukotriene B4 (LTB4) synthesis. It exhibits anti-inflammatory properties by reducing LTB4 and thymic stromal lymphopoietin (TSLP) levels. Halometasone is widely utilized in research related to psoriasis and other eczematous skin disorders, providing insights into corticosteroid-mediated effects on inflammatory pathways. -
Leukotriene Synthesis Inhibitor
L-674573 is a quinoline compound that functions as a selective inhibitor of leukotriene synthesis. It effectively inhibits leukotriene production induced by Calcimycin and N-Formyl-Met-Leu-Phe, with IC50 values of 100 nM and 50 nM, respectively. L-674573 specifically targets and inhibits the translocation of 5-lipoxygenase, making it a valuable tool for research into inflammatory processes and leukotriene-related diseases. Its application is particularly relevant in studies aimed at understanding leukotriene signaling pathways and developing anti-inflammatory therapeutics. -
Leukotriene Inhibitor
Piriprost potassium is a potent leukotriene synthesis inhibitor. It effectively suppresses the release of leukotrienes and histamine in isolated porcine lung cells, exhibiting an IC50 of 0.11 μM. Additionally, Piriprost potassium enhances alkaline phosphatase (ALP) activity in cultured endometrial stromal cells, making it a useful tool for research in inflammation and reproductive biology. -
Leukotriene Formation Inhibitor
Pirodomast is a potent leukotriene formation inhibitor that targets the release of leukotriene D4 (LTD4) and thromboxane B2 in anaphylactic guinea pig lung tissues. With IC50 values of 3.9 μM for LTD4 and 1.9 μM for thromboxane B2, Pirodomast demonstrates significant inhibitory activity. This compound is valuable for research applications related to asthma and inflammatory responses, providing insights into leukotriene-mediated pathways in respiratory conditions. -
cPLA2α Inhibitor
ZPL-5212372 is a potent inhibitor of cytosolic phospholipase A2 alpha (cPLA2α) with an IC50 of 7 nM. This compound efficiently reduces the release of key inflammatory mediators such as prostaglandin D2, cysteinyl leukotrienes, leukotriene B4, and thromboxane A2 from human lung cells. Research indicates that ZPL-5212372 effectively attenuates delayed bronchoconstriction and airway hyperresponsiveness in models of allergic inflammation. Consequently, it serves as a valuable tool for investigating mechanisms and potential therapies for asthma. -
Dual Enkephalinase Inhibitor
PL265 is a dual enkephalinase inhibitor that acts as a prodrug of PL254. It effectively inhibits both neutral endopeptidase (neprilysin) and aminopeptidase N, leading to increased local concentrations of enkephalins like Met-Enkephalin and Leu-Enkephalin. This action subsequently activates μ and δ opioid receptors, resulting in a potent analgesic effect. Additionally, PL265's inhibition of leukotriene A4 hydrolase (LTA4H) may further enhance its anti-inflammatory properties by reducing the production of leukotriene B4 (LTB4). This reagent is particularly valuable in non-addictive chronic pain research. -
5-1ipoxygenase Inhibitor/Leukotriene D4 Antagonist
WAY-126299A is an orally active dual inhibitor of 5-lipoxygenase, demonstrating an IC50 of 12.2 μM, and serves as a leukotriene D4 antagonist with a pKB of 6.4. This compound effectively inhibits antigen-induced leukotriene-dependent bronchoconstriction. WAY-126299A is valuable in research related to asthma and other inflammatory conditions where leukotriene signaling plays a critical role. -
LTE4 Inhibitor
LY 245769 is a leukotriene E4 (LTE4) inhibitor that functions as an omega-trifluoro analog. It exhibits inhibitory activity by interfering with the omega-oxidation of N-acetyl-LTE4 and leukotriene B4 (LTB4), with an IC50 value of 4 μM. This compound is essential for research on inflammatory processes and bronchoconstriction, contributing to the understanding of leukotriene signaling pathways and their role in respiratory diseases. -
MRP1 Inhibitor
LY329146 is a selective inhibitor of multidrug resistance protein 1 (MRP1). It effectively inhibits the transport of leukotriene C4 (LTC4) with an IC50 of 0.8 μM. This compound is valuable for studies exploring multidrug resistance mechanisms and may have applications in enhancing the efficacy of chemotherapy in resistant cancer cells. -
Leukotriene Receptor Inhibitor
12(S)-HEPE is a monohydroxy fatty acid that acts as a leukotriene receptor inhibitor. It is synthesized from eicosapentaenoic acid (EPA) through the action of 12-lipoxygenase (12-LO). In unstimulated neutrophils, 12(S)-HEPE is metabolized to 12(S),20-diHEPE, while stimulated neutrophils generate 5(S),12(S)-HEPE via the 5-lipoxygenase pathway. Its competitive inhibition of arachidonic acid as a substrate for 5-lipoxygenase in leukotriene formation supports its potential anti-inflammatory effects associated with omega-3 fatty acids. -
LTA4H Inhibitor
JNJ-40929837 is a selective and orally active inhibitor of leukotriene A4 hydrolase (LTA4H). This compound effectively inhibits aminopeptidase activity, resulting in the accumulation of Pro-Gly-Pro in serum. JNJ-40929837 is primarily utilized in asthma research to explore its potential therapeutic effects and mechanisms of action related to inflammatory responses. -
Leukotriene Inhibitor
SCH 40120 is a potent leukotriene inhibitor that exhibits significant anti-inflammatory properties. This compound effectively suppresses T cell proliferation as well as both antigen-specific and polyclonal antibody responses in vitro. SCH 40120 also diminishes edematous responses and inhibits the recruitment of circulating neutrophils to inflamed tissues, making it a valuable tool in research related to anti-psoriatic agents. -
LTA4H Inhibitor
JNJ-40929837 succinate is a selective and orally active inhibitor of leukotriene A4 hydrolase (LTA4H). This compound effectively inhibits aminopeptidase activity, leading to the accumulation of Pro-Gly-Pro in serum. JNJ-40929837 succinate is particularly relevant for asthma research, providing a valuable tool for investigating inflammatory pathways and potential therapeutic interventions in respiratory conditions. -
Leukotriene Receptor Inhibitor
(R)-Ontazolast is a potent leukotriene receptor inhibitor that effectively blocks leukotriene biosynthesis. It demonstrates a remarkable IC50 value of 0.001 µM in human polymorphonuclear leukocytes, inhibiting the release of arachidonic acid. This compound is valuable for research applications related to inflammation and immune response modulation. -
Leukotriene B4 Inhibitor
Chamazulene is a natural compound that acts as an inhibitor of leukotriene B4 formation. Its antioxidant properties contribute to modulating inflammatory responses, making it relevant for research in inflammation and immune response studies. Chamazulene is particularly useful in exploring pathways related to leukotriene signaling and its role in various pathologies. -
Leukotriene Inhibitor
FK-664 is a potent leukotriene inhibitor that enhances ventricular contractility and reduces the time to peak tension in cardiac cells. In canine models of heart failure, FK-664 has been shown to decrease mean circulating pressure (MCP), indicating its potential therapeutic effects. This compound is valuable for research focused on cardiovascular diseases, particularly heart failure, and its underlying mechanisms. -
Leukotriene Receptor/FLAP Inhibitor
(S)-Veliflapon is a potent inhibitor of leukotriene biosynthesis targeting the 5-lipoxygenase activating protein (FLAP). It effectively inhibits the formation of leukotriene B4 (LTB4) in rat, mouse, and human leukocytes with IC50 values of 0.026 µM, 0.039 µM, and 0.22 µM, respectively. Additionally, (S)-Veliflapon demonstrates enantioselectivity in human whole blood, making it a valuable reagent for research in inflammation and related biological processes. -
Leukotriene Biosynthesis Inhibitor
L-691678 is an inhibitor of leukotriene biosynthesis that selectively binds to the 5-lipoxygenase-activating protein (FLAP). This compound disrupts leukotriene production, making it a valuable tool for investigating leukotriene-associated pathologies, including allergic responses, asthma, and inflammatory conditions. Its ability to modulate leukotriene levels provides insights into their role in various biological processes and disease mechanisms. -
Leukotriene Biosynthesis Inhibitor
ABT-080 is an orally active inhibitor of leukotriene biosynthesis, specifically targeting the pathways responsible for the production of LTB4 and LTC4. This compound effectively prevents bronchoconstriction, making it valuable for research into asthma and related inflammatory conditions. By selectively inhibiting leukotriene synthesis without affecting PGH2 biosynthesis, ABT-080 provides a critical tool for studying the role of leukotrienes in respiratory diseases. -
LTB4 Inhibitor
Ontazolast is a potent inhibitor of leukotriene B4 (LTB4) biosynthesis, making it a valuable tool for studying inflammatory pathways. Its primary mechanism targets the LTB4 synthesis pathway, which is associated with various inflammatory conditions. Ontazolast is particularly relevant in research applications focused on asthma and related respiratory disorders. -
Leukotriene Receptor Inhibitor
Bunaprolast is a potent leukotriene receptor inhibitor that effectively reduces LTB4 production in human whole blood. Additionally, it demonstrates significant inhibition of lipoxygenase activity and TXB2 release. This compound is valuable for research applications related to inflammatory diseases and respiratory conditions. -
Leukotriene Receptor Inhibitor
LTB4-IN-1 is a selective leukotriene receptor inhibitor, effectively blocking leukotriene B4 synthesis with an IC50 of 70 nM. This compound serves as a valuable tool for research in inflammation and immune response, potentially aiding in the investigation of leukotriene-mediated pathophysiological conditions. Its application can extend to studies focused on cellular signaling and therapeutic interventions targeting leukotriene pathways. -
Spns2 Inhibitor
SLF1081851 is a selective inhibitor of Spns2, effectively inhibiting sphingosine-1-phosphate (S1P) release with an IC50 of 1.93 μM. This compound is crucial for studying developmental processes and immune responses, making it a valuable tool in research focused on modulating these biological pathways. Its ability to target Spns2 provides insight into the mechanisms regulating S1P availability and its subsequent effects on cell signaling and function. -
Spns2 Inhibitor
SLF80821178 is a potent inhibitor of the Sphingosine-1-Phosphate Transporter (Spns2), exhibiting an IC50 of 51 nM for the inhibition of S1P release in HeLa cells. This orally active compound demonstrates a half-life of 2.4 hours in mouse models. Research applications include the investigation of sphingosine metabolism and transport in cellular signaling pathways. -
S1P Lyase Inhibitor
2-Acetyl-4-tetrahydroxybutyl imidazole is a potent inhibitor of sphingosine-1-phosphate (S1P) lyase, demonstrating significant biological activity in vivo. This compound is useful for investigating the role of S1P metabolism in various physiological and pathological processes. Research applications include studying cell signaling pathways and exploring therapeutic targets in diseases related to S1P dysregulation. -
LPL Receptor Inhibitor
S1PR1 modulator 1 is a selective inhibitor of the S1PR1 receptor, demonstrating a pIC50 of 7.6 and exhibiting greater than 40-fold selectivity over S1PR2 and over 80-fold selectivity over S1PR3 and S1PR4. This compound is valuable for investigating S1PR1-mediated signaling pathways and its role in various biological processes, including immune response regulation and cardiovascular function. Its specificity makes it an important tool for research applications focused on the modulation of S1P receptor activity in disease models. -
Autotaxin Inhibitor
CRT0273750 is an inhibitor of autotaxin (ATX), which plays a crucial role in the modulation of lysophosphatidic acid (LPA) levels, exhibiting an IC50 of 0.014 μM. This compound is valuable in the study of ATX/LPA-dependent cancer models, contributing to research on tumor progression and metastasis. Its specificity for ATX provides a useful tool for elucidating the underlying mechanisms of LPA-mediated signaling pathways in various biological contexts. -
S1PL Inhibitor
LX2931 is an inhibitor of Sphingosine 1-Phosphate Lyase (S1PL), which functions by elevating levels of Sphingosine 1-Phosphate (S1P) both intracellularly and extracellularly. This inhibition results in a marked increase in S1P concentrations in lymphoid tissues, potentially leading to restricted lymphocyte trafficking from secondary immune sites and contributing to lymphocytopenia and immunosuppressive effects in the peripheral circulation. LX2931 is valuable for research in autoimmune disease studies, particularly in the context of rheumatoid arthritis. -
S1PL Inhibitor
A6770 is a potent inhibitor of sphingosine 1-phosphate lyase (S1PL), an enzyme involved in sphingolipid metabolism. As an orally active compound, A6770 is phosphorylated to exert direct inhibitory effects on S1PL, leading to an increase in [3H]dhS1P levels. This reagent is valuable for research applications focused on sphingolipid signaling pathways and their roles in various biological processes. -
S1PR5 Antagonist, S1PR5 Inhibitor
S1PR5-IN-1 is a selective antagonist of the sphingosine-1-phosphate receptor 5 (S1PR5), exhibiting an IC50 of 85.4 nM in human assays and a binding affinity (Ka) of 2.173 nM. This orally bioavailable inhibitor effectively impedes the migration of natural killer cells towards sphingosine-1-phosphate. S1PR5-IN-1 is a valuable tool for research applications related to multiple sclerosis and other conditions involving S1PR5 signaling pathways. -
Spns2 Inhibitor
SLB1122168 is a selective inhibitor of Spns2 that significantly impairs the release of sphingosine-1-phosphate (S1P) with an IC50 of 94 nM. This compound is useful for investigating the role of S1P in various biological processes, including immune response and cardiovascular regulation. Its application in research can help elucidate the mechanisms underlying Spns2 activity and S1P signaling pathways. -
Sphingosine-1-phosphate Lyase Inhibitor
S1PL-IN-1 is a selective sphingosine-1-phosphate lyase inhibitor with an IC50 of 210 nM. This compound exhibits potential in modulating S1P signaling pathways and may serve as a Smoothened receptor antagonist with an IC50 of 440 nM. S1PL-IN-1 is primarily utilized in the study of experimental autoimmune encephalomyelitis and related neurological disorders. Its capacity to influence sphingolipid metabolism makes it a valuable tool for research into neuroinflammatory conditions. -
Spns2 Inhibitor
SLF1081851 TFA is a selective inhibitor of Spns2, effectively inhibiting sphingosine-1-phosphate (S1P) release with an IC50 of 1.93 μM. This compound is instrumental in studies related to developmental biology and immune regulation. Its ability to modulate S1P levels makes it a valuable tool for investigating pathways involved in immune responses and developmental processes. -
hS1PL Inhibitor
RBM10-8 is an irreversible inhibitor of recombinant human sphingosine-1-phosphate lyase (hS1PL). This compound modulates the sphingosine-1-phosphate (S1P) signaling pathway, which plays a critical role in regulating various biological processes including cell proliferation, differentiation, angiogenesis, and immune responses. RBM10-8 is valuable for research applications focused on inflammation and developmental biology, providing insights into the therapeutic potential of targeting S1P-related pathways. -
Spns2 Inhibitor
SLF80821178 hydrochloride is a selective inhibitor of the sphingosine-1-phosphate transporter (Spns2), effectively reducing sphingosine-1-phosphate (S1P) release in HeLa cells with an IC50 value of 51 nM. This compound demonstrates the capability to decrease circulating lymphocyte levels in mice without altering plasma S1P concentrations, making it a valuable tool for studying immune response and signaling pathways. Research applications include investigations into lymphocyte trafficking and potential therapeutic strategies targeting sphingosine metabolism. -
Spns2 Inhibitor
SLF1081851 hydrochloride is a potent inhibitor of Spns2, effectively suppressing sphingosine-1-phosphate (S1P) release with an IC50 of 1.93 μM. This compound is significant for research into immune system development and related biological processes. It serves as a valuable tool for investigating the role of S1P in various cellular functions and pathological conditions. -
SPL Inhibitor
SPL-IN-1 is a selective sphingosine-1-phosphate lyase inhibitor that targets the SPL enzyme. It has demonstrated significant biological activity in modulating sphingolipid metabolism and influencing cellular signaling pathways. This compound is valuable for research applications involving inflammation, cancer progression, and other diseases associated with sphingosine-1-phosphate signaling dysregulation. -
S1PL Inhibitor
S1PL-IN-2 is a potent sphingosine-1-phosphate lyase (S1PL) inhibitor with an IC50 of 120 nM. It effectively inhibits S1PL activity by blocking the conversion of Vitamin B6 into the active cofactor pyridoxal-4-phosphate, which is essential for S1P lyase function. This compound is valuable for research in inflammation and immunology, with potential applications in studying conditions such as rheumatoid arthritis. -
LPA Inhibitor
L-NASPA ammonium is an effective LPA inhibitor that targets lysophosphatidic acid signaling pathways. It is utilized in research focused on platelet activation and related cellular processes. By inhibiting LPA, this compound aids in elucidating the mechanisms underlying platelet function and potential therapeutic interventions in related disorders. -
SPNS2 Inhibitor
Spns2-IN-3 is a selective SPNS2 inhibitor that targets sphingolipid metabolism. This compound exhibits significant biological activity in modulating sphingolipid pathways, making it crucial for research applications involving cellular signaling and lipid biology. Its unique structure may facilitate the development of drug carriers, enhancing the delivery and penetration of therapeutic molecules across biological membranes, particularly in dermatological settings. -
LPA Inhibitor
L-NASPA is a potent lysophosphatidic acid (LPA) inhibitor that plays a significant role in research related to platelet activation. By blocking LPA signaling pathways, L-NASPA enables the investigation of its effects on cellular processes involved in thrombosis and inflammation. This compound is valuable for studies aimed at understanding the physiological and pathological roles of LPA in various biological contexts. -
Dopamine Receptor Inhibitor
SV 293 is a selective antagonist that primarily targets dopamine D2 receptors with a binding affinity that is 100-fold greater than that of D3 and D4 receptor subtypes. This compound exhibits neutral antagonist activity and effectively blocks the effects of the full agonist quinpirole in forskolin-dependent adenylate cyclase inhibition assays and electrophysiological assays. SV 293 serves as a valuable pharmacological tool for investigating the role of D2-like receptor subtypes in dopamine-related pathways associated with neurological, neuropsychiatric, and movement disorders. -
Dopamine Uptake Inhibitor
GBR-12879 dihydrochloride is a potent dopamine uptake inhibitor that selectively targets the dopamine transporter. Its primary mechanism involves preventing the reabsorption of dopamine, thus enhancing dopaminergic signaling. This compound is widely utilized in research to investigate the role of dopamine in neurological disorders and to explore potential therapeutic strategies for conditions such as depression and schizophrenia. -
DAT/NET/SERT Inhibitor
Amitifadine is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that targets the dopamine transporter (DAT), norepinephrine transporter (NET), and serotonin transporter (SERT). It exhibits inhibitory concentrations of 12 nM for serotonin, 23 nM for norepinephrine, and 96 nM for dopamine in HEK 293 cells. This compound is pertinent for research applications exploring the modulation of monoaminergic systems and investigating potential therapeutic effects in mood disorders.
